Reagents News and Research

RSS

The Native Antigen Company introduces new range of influenza antigens

The Native Antigen Company (part of LGC Clinical Diagnostics), one of the world’s leading suppliers of reagents that enables research into vaccines and diagnostics for emerging and endemic infectious diseases, today announced the commercial launch of its latest range of influenza antigens for the southern hemisphere’s 2023 flu season.

From The Native Antigen Company 21 Nov 2022

CRISPR technology to improve the efficacy of immunotherapy

Using CRISPR technology for the first time, researchers have inserted genes that enable immune cells to concentrate their attack on cancer cells, potentially sparing healthy cells and boosting the effectiveness of immunotherapy.

14 Nov 2022

Testing for residual solvents and terpenes in cannabis

AZoLifeSciences sat down with Tom Kwoka, Senior Application Scientist - GC/MS at PerkinElmer, and Alex Maitain, GC/MS Cannabis Analysis at PerkinElmer, to discuss the benefits of analyzing residual solvents and terpenes from cannabis and hemp products by Headspace GC/MS analysis.

From PerkinElmer 8 Nov 2022

The Native Antigen Company expands its range of Omicron antigens to include BA.5 variant

The Native Antigen Company (part of LGC Clinical Diagnostics), one of the world’s leading suppliers of reagents that enables research into vaccines and diagnostics for emerging and endemic infectious diseases, today announced the commercial launch of its latest SARS-CoV-2 antigens for the newly designated Omicron BA.5 variant.

From The Native Antigen Company 7 Nov 2022

Types of elution methods for cannabis analysis

In this interview, PerkinElmer, talks to AZoLifeSciences about the types of elution methods for cannabis analysis.

From PerkinElmer 7 Sep 2022

Reservoir ensures sustainable use of reagents

Manufactured to the ANSI/SLAS standard, the range of reagent reservoirs from Porvair Sciences are designed for simple integration into any automated liquid handling system.

From Porvair Sciences Limited 24 Aug 2022

Re-defining the limits of single batch assay stabilisation

In response to increasing demand for stabilised molecular diagnostic assays, we have significantly increased our single batch lyophilised reagent bead manufacturing throughput to 300,000 reactions per freeze drying run and are now progressing towards a capacity of 100 million tests per annum.

From Biofortuna Limited 22 Aug 2022

Study provides guidelines on how to design safer CRISPR reagents

The 2020 Nobel Prize in Chemistry was awarded to Jennifer A. Doudna and Emmanuelle Charpentier for developing the widely utilized and incredibly precise genome editing method known as CRISPR/Cas9

11 Aug 2022

New method can easily convert commercially available DNA chips into RNA chips

Biochips (microarrays) are modern analytical tools that allow thousands of individual detections to be performed simultaneously in a small amount of sample material. A team led by Mark Somoza from the Faculty of Chemistry at the University of Vienna has now presented a new method in "Nature Communications".

27 Jul 2022

Challenges in Drug Discovery; Where are we now, and where are we going?

As part of our SLAS Europe 2022 coverage, we speak to Steve Rees, Vice-President of Discovery Biology at AstraZeneca, about the challenges currently faced by the drug discovery sector.

From Society for Laboratory Automation and Screening (SLAS) 8 Jul 2022

INTEGRA pipettes simplify PCR testing for COVID-19

Matrix Diagnostics – a dedicated COVID-19 testing lab in California – is relying on INTEGRA Biosciences’ EVOLVE and MINI 96 pipettes to streamline and accelerate its PCR workflows

From INTEGRA Biosciences 21 Jun 2022

INTEGRA solutions helping to support a new generation of RNA sequencing

INTEGRA Biosciences’ electronic handheld pipetting solutions are helping to improve the throughput capacity of bulk RNA barcoding and sequencing (BRB-seq) at Alithea Genomics in Switzerland.

From INTEGRA Biosciences 17 Jun 2022

Axol Bioscience introduces CiPA-validated human stem cell-derived ventricular cardiomyocytes to help improve drug discovery

Axol Bioscience Ltd. (Axol), an established provider of iPSC-derived cells, media, and characterization services for life science discovery, today announced that its human induced pluripotent stem cell (iPSC)-derived ventricular cardiomyocytes have undergone comprehensive in vitro pro-arrhythmia assay (CiPA) validation.

From Axol Bioscience Ltd 8 Jun 2022

Reagents News and Research

The Native Antigen Company introduces new range of influenza antigens

CRISPR technology to improve the efficacy of immunotherapy

Testing for residual solvents and terpenes in cannabis

The Native Antigen Company expands its range of Omicron antigens to include BA.5 variant

Types of elution methods for cannabis analysis

Reservoir ensures sustainable use of reagents

Re-defining the limits of single batch assay stabilisation

Study provides guidelines on how to design safer CRISPR reagents

New method can easily convert commercially available DNA chips into RNA chips

Challenges in Drug Discovery; Where are we now, and where are we going?

INTEGRA pipettes simplify PCR testing for COVID-19

INTEGRA solutions helping to support a new generation of RNA sequencing

Axol Bioscience introduces CiPA-validated human stem cell-derived ventricular cardiomyocytes to help improve drug discovery

Rapidly growing nanotechnology firm launches new identity as MIP Discovery

Pesticide testing workflow for cannabis and hemp products

eTesting cannabis for impurities and contaminants

Arrayjet introduces Mercury range of next-generation microarray printers

Using a microfluidic chip for selection of healthy sperm based on positive rheotaxis

INTEGRA’s ASSIST PLUS pipetting robot helps to streamline sample pooling for arbovirus testing

MIP Diagnostics secures £7.3M investment following achievement of critical milestones

The Last Piece of Our Genome: Sequencing the Y Chromosome

Understanding the Importance of Entrepreneurship in the Life Sciences Community

Supporting Informed Decisions on Malaria Biocontrol Interventions

Latest in Genomics